港股異動丨康希諾生物高開9.46% 已開始針對新突變株“奧密克戎”開展疫苗研發
格隆匯11月29日丨康希諾生物-B(06185.HK)高開9.46%,報167.8港元;康希諾(688185.SH)競價階段則漲逾9%。近期,新冠病毒變異毒株奧密克戎(Omicron)對新冠疫苗的影響備受關注。從康希諾生物股份公司獲悉,公司對奧密克戎(Omicron)變異株高度關注,目前正在收集和分析相關的信息。據悉,康希諾生物已經開始針對新突變株開展疫苗研發,相關人士表示:“鑑於康希諾生物腺病毒載體技術平台和mRNA技術平台的優勢,一旦發現現有疫苗保護性下降,康希諾有信心在最短時間拿出針對突變株的新疫苗。”

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.